210 related articles for article (PubMed ID: 34269714)
1. Survival benefit of endocrine dysfunction following immune checkpoint inhibitors for nonthyroidal cancers.
Kotwal A; Ryder M
Curr Opin Endocrinol Diabetes Obes; 2021 Oct; 28(5):517-524. PubMed ID: 34269714
[TBL] [Abstract][Full Text] [Related]
2. Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors.
Iwama S; Kobayashi T; Arima H
Endocrinol Metab (Seoul); 2021 Apr; 36(2):312-321. PubMed ID: 33934588
[TBL] [Abstract][Full Text] [Related]
3. Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management.
Del Rivero J; Cordes LM; Klubo-Gwiezdzinska J; Madan RA; Nieman LK; Gulley JL
Oncologist; 2020 Apr; 25(4):290-300. PubMed ID: 32297436
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
Kotwal A; Kottschade L; Ryder M
Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
[No Abstract] [Full Text] [Related]
5. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
6. Effects of immune checkpoint inhibitor associated endocrinopathies on cancer survival.
Yang L; Murthy S; Cortellini A; Lim EA; Gonzalez M; Pinato DJ; Abdel-Malek M; Mahmoud S; Martin NM
Front Endocrinol (Lausanne); 2024; 15():1369268. PubMed ID: 38681767
[TBL] [Abstract][Full Text] [Related]
7. Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review.
Stelmachowska-Banaś M; Czajka-Oraniec I
Endocr Connect; 2020 Oct; 9(10):R207-R228. PubMed ID: 33064663
[TBL] [Abstract][Full Text] [Related]
8. Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
Akamatsu H; Murakami E; Oyanagi J; Shibaki R; Kaki T; Takase E; Tanaka M; Harutani Y; Yamagata N; Okuda Y; Furuta K; Sugimoto T; Teraoka S; Hayata A; Tokudome N; Ozawa Y; Mori K; Koh Y; Yamamoto N
Oncologist; 2020 Apr; 25(4):e679-e683. PubMed ID: 32297443
[TBL] [Abstract][Full Text] [Related]
9. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
10. Endocrine immune-related adverse effects of immune-checkpoint inhibitors.
Trevisani V; Iughetti L; Lucaccioni L; Predieri B
Expert Rev Endocrinol Metab; 2023; 18(5):441-451. PubMed ID: 37682107
[TBL] [Abstract][Full Text] [Related]
11. Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responses.
Blum SM; Rouhani SJ; Sullivan RJ
Immunol Rev; 2023 Sep; 318(1):167-178. PubMed ID: 37578634
[TBL] [Abstract][Full Text] [Related]
12. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
Bhatlapenumarthi V; Patwari A; Harb AJ
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
[TBL] [Abstract][Full Text] [Related]
13. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors.
Kurimoto C; Inaba H; Ariyasu H; Iwakura H; Ueda Y; Uraki S; Takeshima K; Furukawa Y; Morita S; Yamamoto Y; Yamashita S; Katsuda M; Hayata A; Akamatsu H; Jinnin M; Hara I; Yamaue H; Akamizu T
Cancer Sci; 2020 May; 111(5):1468-1477. PubMed ID: 32086984
[TBL] [Abstract][Full Text] [Related]
14. Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors.
Choi J; Lee SY
Immune Netw; 2020 Feb; 20(1):e9. PubMed ID: 32158597
[TBL] [Abstract][Full Text] [Related]
15. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.
Matsuoka H; Hayashi T; Takigami K; Imaizumi K; Shiroki R; Ohmiya N; Sugiura K; Kawada K; Sawaki A; Maeda K; Ando Y; Uyama I
BMC Cancer; 2020 Jul; 20(1):656. PubMed ID: 32664888
[TBL] [Abstract][Full Text] [Related]
16. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
[TBL] [Abstract][Full Text] [Related]
17. Challenges and Limitations of Endocrine Toxicity Evaluation in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy-Retrospective Study from a Tertiary-Level Hospital in Romania.
Coniac S; Costache Outas MC; Pirvu EE; Patru RI; Gainariu E; Aldea C; Iorga PG; Ambroci M; Liscu HD; Miron AI; Badiu C
Diagnostics (Basel); 2023 May; 13(10):. PubMed ID: 37238273
[TBL] [Abstract][Full Text] [Related]
18. Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy.
Chye A; Allen I; Barnet M; Burnett DL
Front Oncol; 2022; 12():894015. PubMed ID: 35912205
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics and potential biomarkers of thyroid and pituitary immune-related adverse events.
Kobayashi T; Iwama S; Arima H
Endocr J; 2024 Jan; 71(1):23-29. PubMed ID: 37940567
[TBL] [Abstract][Full Text] [Related]
20. Quantitation of cardiac troponin I in cancer patients treated with immune checkpoint inhibitors: a case-control study.
Ulndreaj A; Brinc D; Altan M; Pons-Belda OD; Fernandez-Uriarte A; Mu-Mosley H; Fattah F; von Itzstein MS; Soosaipillai A; Kulasingam V; Palaskas NL; Gerber DE; Diamandis EP; Heymach JV; Prassas I
Clin Chem Lab Med; 2023 Jan; 61(1):154-161. PubMed ID: 36287134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
